WOBE437
Pharmaceutical compound
From Wikipedia, the free encyclopedia
WOBE437 is a selective endocannabinoid reuptake inhibitor (SERI) which has been used in scientific research.[1][2]
- None
 | |
| Clinical data | |
|---|---|
| Other names | WOBE-437 |
| Drug class | Selective endocannabinoid reuptake inhibitor (SERI) |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C22H33NO3 |
| Molar mass | 359.510 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is a highly potent and selective endocannabinoid reuptake inhibitor, with an IC50 of 10 nM in terms of this action.[1][2][3] The drug produces anxiolytic-like, anti-inflammatory, analgesic, antiallodynic, and muscle relaxant effects in rodents.[1][2][4] These effects are mediated by increased endocannabinoid levels, including of anandamide (AEA) and 2-arachidonylglycerol (2-AG), and are dependent on cannabinoid receptors, for instance the cannabinoid CB1 receptor.[1][2] Conversely, WOBE437 did not produce catalepsy, affect locomotor activity, or produce the typical sedation of cannabinoid CB1 receptor agonists.[2][4] The drug also showed effectiveness in an animal model of multiple sclerosis.[4] Originally believed to be selective, off-target activities of WOBE437 have subsequently been identified and described.[5]
WOBE437 is orally bioavailable in rodents.[2]
Numerous analogues of WOBE437 have been explored in search of candidates with better drug-like properties, though a series of almost 80 compounds found none that were more potent than WOBE437 itself.[3]
WOBE437 was first described in the scientific literature by 2013.[6][1]
